Increasing Access to Biosimilars Act of 2023
Latest Action
Read twice and referred to the Committee on Finance.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Increasing Access to Biosimilars Act of 2023 is a Senate bill introduced in the 118th Congress aimed at improving the availability of biosimilar drugs. Biosimilars are medically equivalent versions of biologic drugs that can offer more affordable treatment options. Although the bill text and official summary are not provided, the bill's title and policy area indicate a focus on health policy, specifically on expanding access to biosimilar medications. The bill was read twice and referred to the Senate Committee on Finance but ultimately failed or expired without further legislative action.
This bill sought to enhance access to biosimilar drugs to potentially reduce healthcare costs and increase treatment options but did not advance beyond committee referral in the 118th Congress.
- The bill is focused on increasing access to biosimilar drugs, which are alternatives to brand-name biologics.
- It was introduced in the Senate during the 118th Congress and referred to the Committee on Finance.
- The bill did not progress past committee and is currently classified as failed or expired.
['Patients requiring biologic treatments who may gain access to more affordable biosimilar options', 'Healthcare providers prescribing biologic medications', 'Pharmaceutical companies involved in biosimilar development and distribution', 'Health insurance providers potentially benefiting from cost savings']
['Lack of detailed bill text limits understanding of specific implementation mechanisms or funding provisions', "Potential challenges in regulatory approval processes for biosimilars may affect the bill's effectiveness", 'Oversight and enforcement provisions are unknown due to missing full text', 'Cost implications for government healthcare programs and private insurers are not specified']
The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Finance on March 14, 2024. It did not advance further and is now classified as failed or expired. The policy area is health, reflecting ongoing legislative interest in improving access to affordable medications, particularly biosimilars, which have been a focus in efforts to reduce healthcare costs.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Increased availability of biosimilars could lead to reduced overall healthcare spending on biologic drugs.', 'Greater competition in the biologics market may incentivize innovation or pricing adjustments by pharmaceutical companies.', 'Potential shifts in prescribing practices among healthcare providers toward biosimilars.']
Transparency is limited due to the absence of the full bill text and official summary, restricting comprehensive analysis. Monitoring future legislative efforts on biosimilars should include detailed review of implementation, funding, and enforcement provisions to assess potential impacts fully.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.